These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 27392463

  • 1. Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
    Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
    Clin Immunol; 2016 Aug; 169():139-147. PubMed ID: 27392463
    [Abstract] [Full Text] [Related]

  • 2. Reprint of "Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis".
    Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
    Clin Immunol; 2017 Dec; 185():119-127. PubMed ID: 29111236
    [Abstract] [Full Text] [Related]

  • 3. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ.
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.
    Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ.
    Am J Pathol; 2011 Jul; 179(1):116-24. PubMed ID: 21703397
    [Abstract] [Full Text] [Related]

  • 5. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.
    Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, Anders HJ.
    J Am Soc Nephrol; 2007 Aug; 18(8):2350-8. PubMed ID: 17625118
    [Abstract] [Full Text] [Related]

  • 6. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 7. The fungal lactone oxacyclododecindione is a potential new therapeutic substance in the treatment of lupus-associated kidney disease.
    Henke J, Erkel G, Brochhausen C, Kleinert H, Schwarting A, Menke J, Pautz A.
    Kidney Int; 2014 Oct 15; 86(4):780-9. PubMed ID: 24717299
    [Abstract] [Full Text] [Related]

  • 8. CCL2/MCP-1 and CXCL12/SDF-1 blockade by L-aptamers improve pancreatic islet engraftment and survival in mouse.
    Citro A, Pellegrini S, Dugnani E, Eulberg D, Klussmann S, Piemonti L.
    Am J Transplant; 2019 Nov 15; 19(11):3131-3138. PubMed ID: 31267721
    [Abstract] [Full Text] [Related]

  • 9. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice.
    Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S.
    Arthritis Rheum; 2003 Sep 15; 48(9):2555-66. PubMed ID: 13130475
    [Abstract] [Full Text] [Related]

  • 10. Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice.
    Shimizu S, Nakashima H, Karube K, Ohshima K, Egashira K.
    Clin Exp Rheumatol; 2005 Sep 15; 23(2):239-42. PubMed ID: 15895897
    [Abstract] [Full Text] [Related]

  • 11. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice.
    Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M.
    Rheumatology (Oxford); 2004 Sep 15; 43(9):1121-8. PubMed ID: 15213333
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice.
    Hu L, Hu J, Chen L, Zhang Y, Wang Q, Yang X.
    Front Immunol; 2021 Sep 15; 12():584414. PubMed ID: 33717066
    [Abstract] [Full Text] [Related]

  • 13. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
    Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D.
    J Am Soc Nephrol; 2004 Jun 15; 15(6):1504-13. PubMed ID: 15153561
    [Abstract] [Full Text] [Related]

  • 14. PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.
    Zhai JX, Zhang ZX, Feng YJ, Ding SS, Wang XH, Zou LW, Ye DQ.
    Mol Biol Rep; 2012 Jun 15; 39(6):6763-71. PubMed ID: 22318546
    [Abstract] [Full Text] [Related]

  • 15. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, Lai KN.
    Lupus; 2002 Jun 15; 11(7):411-8. PubMed ID: 12195781
    [Abstract] [Full Text] [Related]

  • 16. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis.
    Chan RW, Lai FM, Li EK, Tam LS, Wong TY, Szeto CY, Li PK, Szeto CC.
    Arthritis Rheum; 2004 Sep 15; 50(9):2882-90. PubMed ID: 15457456
    [Abstract] [Full Text] [Related]

  • 17. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 15; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 18. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.
    J Am Soc Nephrol; 2005 Dec 15; 16(12):3592-601. PubMed ID: 16267157
    [Abstract] [Full Text] [Related]

  • 19. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Liu ZC, Zhou QL, Li XZ, Yang JH, Ao X, Veeraragoo P, Zuo XX.
    Cytokine; 2011 Mar 15; 53(3):295-300. PubMed ID: 21163672
    [Abstract] [Full Text] [Related]

  • 20. [CCL2/MCP1: a novel target in systemic lupus erythematosus and lupus nephritis].
    Kulkarni O, Anders HJ.
    Z Rheumatol; 2008 May 15; 67(3):220-4. PubMed ID: 18398619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.